dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
Published 4 years ago • 251 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:32
dr. mcgregor on the future of cabozantinib in rcc
-
1:47
dr. mcgregor on choosing a combination therapy regimen in advanced rcc
-
1:49
dr. mcgregor on immunotherapy combinations in kidney cancer
-
2:06
dr. mcgregor on whether patients need frontline combinations in rcc
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
1:49
dr. mcgregor on new combinations with immunotherapy in rcc
-
1:26
dr mcgregor on the updated nccn guidelines for non–clear cell rcc
-
2:34
nivo cabozantinib vs sunitinib for first-line treatment of arcc
-
0:41
dr. toni choueiri on cabozantinib and nivolumab combination in kidney cancer
-
1:35
checkmate-9er shows efficacy of nivolumab/cabozantinib combo in rcc
-
1:14
dr. mcgregor on the combination of atezolizumab and bevacizumab in rcc
-
6:26
session 5: nivolumab cabozantinib vs sunitinib for advanced rcc | checkmate9er & checkmate214
-
1:22
copy of dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
1:56
checkmate 9er: arcc patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib
-
10:14
dr darshit shah | nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced rcc
-
1:08
dr. mcgregor on unmet needs in non-clear cell rcc
-
2:43
cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced rcc
-
2:47
cabozantinib in mrcc
-
2:09
dr. apolo on cabozantinib plus nivolumab and ipilimumab in urothelial carcinoma